IDH1 and acute myeloid leukemia: Thus, abrogated IDH activity is a target for treatment of R/R IDH-mutated AML, with three FDA-approved IDH inhibitors: ivosidenib (AG-120, IDH1 inhibitor), olutasidenib (FT-2102, IDH1 inhibitor), and enasidenib (AG-221, IDH2 inhibitor) [52, 94-102].